Literature DB >> 20237427

Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.

Seishi Ogawa1, Masashi Sanada, Lee-Young Shih, Takahiro Suzuki, Makoto Otsu, Hiromitsu Nakauchi, H Philip Koeffler.   

Abstract

c-CBL (CBL) encodes a multifunctional protein engaged in the regulation of intracellular signaling pathways. It was first identified as a cellular counterpart of the viral oncogene, v-CBL, that causes murine lymphoma. Although no genetic evidence existed suggesting its role in human carcinogenesis, the recent discovery of c-CBL mutations in myeloid cancers has unveiled a unique oncogenic mechanism mediated by gain-of-function of a mutated tumor suppressor, closely associated with allelic conversion of 11q arms. In this review, we summarize our current knowledge about c-CBL mutations and discuss the molecular mechanisms of their gain-of-function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237427      PMCID: PMC5880622          DOI: 10.4161/cc.9.6.11034

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  50 in total

1.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.

Authors:  K Bachmaier; C Krawczyk; I Kozieradzki; Y Y Kong; T Sasaki; A Oliveira-dos-Santos; S Mariathasan; D Bouchard; A Wakeham; A Itie; J Le; P S Ohashi; I Sarosi; H Nishina; S Lipkowitz; J M Penninger
Journal:  Nature       Date:  2000-01-13       Impact factor: 49.962

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

3.  CAP defines a second signalling pathway required for insulin-stimulated glucose transport.

Authors:  C A Baumann; V Ribon; M Kanzaki; D C Thurmond; S Mora; S Shigematsu; P E Bickel; J E Pessin; A R Saltiel
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 4.  Cbl: many adaptations to regulate protein tyrosine kinases.

Authors:  C B Thien; W Y Langdon
Journal:  Nat Rev Mol Cell Biol       Date:  2001-04       Impact factor: 94.444

5.  Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

Authors:  Michael A Caligiuri; Roger Briesewitz; Jianhua Yu; Lisheng Wang; Min Wei; Kristy J Arnoczky; Trent B Marburger; Jing Wen; Danilo Perrotti; Clara D Bloomfield; Susan P Whitman
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

6.  Coupling of the proto-oncogene product c-Cbl to the epidermal growth factor receptor.

Authors:  H Meisner; M P Czech
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

7.  c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption.

Authors:  S Tanaka; M Amling; L Neff; A Peyman; E Uhlmann; J B Levy; R Baron
Journal:  Nature       Date:  1996-10-10       Impact factor: 49.962

8.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Authors:  Masashi Sanada; Takahiro Suzuki; Lee-Yung Shih; Makoto Otsu; Motohiro Kato; Satoshi Yamazaki; Azusa Tamura; Hiroaki Honda; Mamiko Sakata-Yanagimoto; Keiki Kumano; Hideaki Oda; Tetsuya Yamagata; Junko Takita; Noriko Gotoh; Kumi Nakazaki; Norihiko Kawamata; Masafumi Onodera; Masaharu Nobuyoshi; Yasuhide Hayashi; Hiroshi Harada; Mineo Kurokawa; Shigeru Chiba; Hiraku Mori; Keiya Ozawa; Mitsuhiro Omine; Hisamaru Hirai; Hiromitsu Nakauchi; H Phillip Koeffler; Seishi Ogawa
Journal:  Nature       Date:  2009-07-20       Impact factor: 49.962

9.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

Authors:  Mignon L Loh; Debbie S Sakai; Christian Flotho; Michelle Kang; Manfred Fliegauf; Sophie Archambeault; Charles G Mullighan; Leslie Chen; Eva Bergstraesser; Carlos E Bueso-Ramos; Peter D Emanuel; Henrik Hasle; Jean-Pierre Issa; Marry M van den Heuvel-Eibrink; Franco Locatelli; Jan Stary; Monica Trebo; Marcin Wlodarski; Marco Zecca; Kevin M Shannon; Charlotte M Niemeyer
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

10.  Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Authors:  Norihiko Kawamata; Seishi Ogawa; Go Yamamoto; Soren Lehmann; Ross L Levine; Yana Pikman; Yasuhito Nannya; Masashi Sanada; Carl W Miller; D Gary Gilliland; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2008-08-23       Impact factor: 3.084

View more
  4 in total

1.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.

Authors:  Katrin A Salva; Margo J Reeder; Rita Lloyd; Gary S Wood
Journal:  Am J Dermatopathol       Date:  2017-10       Impact factor: 1.533

3.  A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease.

Authors:  X Peng; M Dong; L Ma; X-E Jia; J Mao; C Jin; Y Chen; L Gao; X Liu; K Ma; L Wang; T Du; Y Jin; Q Huang; K Li; L I Zon; T Liu; M Deng; Y Zhou; X Xi; Y Zhou; S Chen
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

4.  c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/β-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation.

Authors:  Sowmiya Kumaradevan; Shin Yin Lee; Sean Richards; Chimera Lyle; Qing Zhao; Umit Tapan; Yilan Jiangliu; Shmyle Ghumman; Joshua Walker; Mostafa Belghasem; Nkiruka Arinze; Angela Kuhnen; Janice Weinberg; Jean Francis; Kevan Hartshorn; Vijaya B Kolachalama; Daniel Cifuentes; Nader Rahimi; Vipul C Chitalia
Journal:  Am J Pathol       Date:  2018-07-17       Impact factor: 5.770

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.